A pharmaceutical company based in Asia has annual sales of about $160 million with more than 600 employees. The firm’s current marketing portfolio are mostly made of branded products licensed in from overseas partners. For the R&D activity, the firm has several clinical pipelines in the area of CNS and oncology under clinical study in the US, Europe, and Korea. The firm is actively searching for innovative candidates and products around the world to incorporate into its pipeline. Additionally, the firm also seek promising biotech with innovative approach to add into its investment portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.
The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. The firm is also able to invest in a financing round, preferably series A or B. In terms of indications, the firm is interested in movement disorders, CNS, liver disease, and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.
The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third-party relationships.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply